Novaremed

Developing tyrosine kinase modulator for the treatment of neuropathic pain

placePetah Tikva, Central District, Israel calendar_todayFounded 2008 groups10 employees language novaremed.com

Innovation

12 patent families (9 granted) — focus: Chemistry & metallurgy, Human necessities; filing pace slowing. Cited 596 times.

YearFilings
20147
20157
20167
20173
20181
20193
20203
20211
20222
20231
20241
20251

Social engagement

Social engagement: 983 social following, 1 post in the last 12 months — below the industry typical range.

Investor mix

3 investors on record; lead investors include Global Emerging Markets.

Investor typeCountShare
Venture capital133%
Private equity133%
Other / undisclosed133%

Recent activity

2 Sep 2025
Milestone
regulatory
Coming soon